Can-Fite BioPharma Ltd.
CANF · XNYSCIK 1536196fmd_0XXQ141WBN1Z7TP8KG594E42D0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 20 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| Net interest income | – | – | (1) | (1) | (0) | 0 | (0) | – | – | – |
| Realized investment gains (losses) | – | – | – | – | 0 | 0 | – | – | – | – |
| Research and development | 6 | 5 | 6 | 11 | 12 | 10 | 8 | 6 | 6 | 7 |
| Selling, general and administrative | 3 | 3 | 3 | 3 | 0 | 0 | 0 | – | – | – |
| Total operating expenses | – | – | – | – | – | – | 11 | 9 | 9 | 10 |
| Operating income | (9) | (7) | (5) | (12) | (14) | (13) | (10) | (8) | (8) | (10) |
| Interest expense | 0 | 1 | 1 | 1 | – | – | (0) | 1 | 0 | 0 |
| Other non-operating income (expense) | – | 2 | (1) | (1) | (0) | 0 | (0) | 1 | 0 | 0 |
| Income before taxes | (8) | (5) | (7) | (13) | (14) | (13) | (10) | (8) | (8) | (10) |
| Income tax expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Net income from continuing operations | 0 | 0 | (1) | – | – | – | – | – | – | – |
| Net income | 8 | (5) | (7) | (13) | (14) | (13) | (10) | (8) | (8) | (10) |